(UroToday.com) ModraDoc006 is a novel, oral tablet formulation of docetaxel. To enhance bioavailability, it is co-administered with ritonavir (r), an inhibitor of cytochrome P450 3A4 and P-glycoprotein. The oral combination, noted as ModraDoc006/r, has potential advantages in terms of patient convenience, elimination of infusion-related reactions, and avoiding prophylactic steroid administration, as well as safety benefits. At the GU ASCO 2021 annual meeting, Dr. Ulka Vaishampayan and colleagues presented efficacy results of the Phase IIb trial comparing oral ModraDoc006/r to IV docetaxel.